Ferring Pharmaceuticals Overview
Ferring Pharmaceuticals is a research-driven biopharmaceutical company devoted to identifying, developing, and marketing products in the fields of reproductive health, urology, gastroenterology, endocrinology, and orthopedics. The company's research activities and products are connected by a common focus of providing tailored treatments that work on the body's own terms, enabling doctors to combat numerous diseases and medical conditions. With the acquisition of the Israeli company Bio-Technology General (BTG) in 2005, Ferring gained capabilities in recombinant biotechnology as well as more traditional pharmaceutical manufacturing. There are two Ferring sites in Israel: Ferring Pharmaceuticals Israel, a manufacturing and distribution site, and Bio-Technology General, which is involved in the development of recombinant biologics and biotechnology, as well as manufacturing. Ferring and BTG actively search for in-licensing opportunities and product acquisitions in Ferring's key areas of therapeutic activity, reproductive health, endocrinology, urology, gastroenterology, and orthopedics.
Latest News
growth-positive
Israeli startup CytoReason joins forces with Ferring Pharmaceuticals to find new IBD treatment
Israeli startup CytoReason has partnered with Ferring Pharmaceuticals to develop new treatments for inflammatory bowel disease (IBD). CytoReasons AI platform will be used to build cell-centred disease models, allowing Ferring to accelerate drug discovery and reduce costs. The collaboration aims to provide new therapeutic options for IBD patients by identifying top drug targets. CytoReasons computational model simulates human disease on a cellular level, minimizing the need for animal trials and improving the accuracy of human trials. This partnership is the first between the two companies. CytoReasons technology is already used by six of the worlds top 10 pharma firms.
Partners
growth-positive
Ferring, Rebiotix and MyBiotics Collaborate to Develop Live Microbiome-Based Therapeutics in Reproductive Medicine and Maternal Health BioSpace
Ferring Pharmaceuticals, Rebiotix Inc., and MyBiotics Pharma Ltd. have announced a strategic collaboration to develop live microbiota-based biotherapeutics for bacterial vaginosis. The collaboration aims to reduce the need for antibiotics and provide a long-term treatment solution for the common vaginal infection. The agreement combines MyBiotics culturing and delivery technologies with Rebiotixs expertise in microbiota-based products and Ferrings therapeutic development and commercial expertise. The collaboration is an important step forward in harnessing the power of the human microbiome in womens health. The partnership between Ferring and MyBiotics has already successfully piloted technologies for stabilizing bacterial species critical to the female reproductive tract. The collaboration is expected to add several firsts to Ferrings microbiome product pipeline, including the companys first non-donor derived formulation and a live microbiota-based product specific to reproductive medicine.
Partners
growth-positive
https://www.jpost.com/Jpost-Tech/Biotechnology-General-opens-production-line-to-boost-manufacturing-capacity-603348
Biotechnology General (BTG), an Israeli-based company, has launched a production line that increases the capacity of mammalian drug production. The company invested $17 million in setting up the production line, which was established at its facilities in the Beer Tuvia Industrial Area in 2018. Ferring Pharmaceuticals, BTGs parent company, provided the investment. The inauguration of the production line was attended by Ferring President Per Falk, who highlighted the importance of BTG in Ferrings goal of becoming a world leader in reproductive medicine and maternal health. BTG is the oldest biological pharmaceutical company in Israel and has expanded over the years to become significant in the production of genetically engineered drugs.
InvestmentPartners
growth-positive
Ferring looks to Israel for innovative biotech
The article discusses the growth of Swiss company Ferring in the pharmaceutical sector. Ferring has achieved annual revenue of $2 billion by improving the user experience for older products, rather than relying on one bestselling drug. The companys focus on upgrading existing products and expanding into new markets has contributed to its success. Ferring also acquired Bio-Technology General (BTG), an Israeli biotechnology pioneer, which has further strengthened its position in the industry. Ferring is now investing in microbiome products and entering the urological-oncological field. The company aims to reinforce strengths in fertility, urology, and gastroenterology, while also improving access to treatment and the user experience for patients. The article suggests that Ferrings growth strategy could have an impact on the entire pharmaceutical industry.
InvestmentAcquisition
growth-positive
Ferring invests $15m in Israeli unit Bio-Technology General
Ferring Pharmaceuticals is investing $15 million to expand biotech production capabilities at its Israeli subsidiary Bio-Technology General (BTG). The investment will support the development of new treatments in reproductive medicine and womens health, as well as the manufacturing of the active pharmaceutical ingredient for Ferrings latest fertility treatment. The expansion will allow Ferring to maintain its scientific leadership in the fertility field and help more people around the world. BTG, founded in 1980, is the longest-standing bio-pharmaceutical company in Israel and has an R&D and manufacturing facility for female fertility, growth hormone, and osteoarthritis of the knees.
Investment
Team Members
1
Employees: 51-200
Web & Social Links
| Website | www.ferring.com/en/home/ |
Locations
Kiryat Malakhi, Israel
Ha-Shita St 8, Caesarea, Israel
Chem. de la Vergognausaz 50, 1162 Saint-Prex, Switzerland
Photos & Videos
No files yet
Ferring Pharmaceuticals Business
Business models
—
Product stage
—
Employees
51-200
Sector
—Target Customer
—Core Technology
—Tags (6)
biotechnologymedical-devicespharmaceuticalspain-relieffertilitydrug-developmentFerring Pharmaceuticals Financials
—
Total funding
—
Capital raised
—
Last funding
—
Funding stage
—
Total rounds
—
Investors
Ferring Pharmaceuticals Lifecycle
Ferring Pharmaceuticals News
5 articles
growth-positive
Israeli startup CytoReason joins forces with Ferring Pharmaceuticals to find new IBD treatment
Israeli startup CytoReason has partnered with Ferring Pharmaceuticals to develop new treatments for inflammatory bowel disease (IBD). CytoReasons AI platform will be used to build cell-centred disease models, allowing Ferring to accelerate drug discovery and reduce costs. The collaboration aims to provide new therapeutic options for IBD patients by identifying top drug targets. CytoReasons computational model simulates human disease on a cellular level, minimizing the need for animal trials and improving the accuracy of human trials. This partnership is the first between the two companies. CytoReasons technology is already used by six of the worlds top 10 pharma firms.
Partners
growth-positive
Ferring, Rebiotix and MyBiotics Collaborate to Develop Live Microbiome-Based Therapeutics in Reproductive Medicine and Maternal Health BioSpace
Ferring Pharmaceuticals, Rebiotix Inc., and MyBiotics Pharma Ltd. have announced a strategic collaboration to develop live microbiota-based biotherapeutics for bacterial vaginosis. The collaboration aims to reduce the need for antibiotics and provide a long-term treatment solution for the common vaginal infection. The agreement combines MyBiotics culturing and delivery technologies with Rebiotixs expertise in microbiota-based products and Ferrings therapeutic development and commercial expertise. The collaboration is an important step forward in harnessing the power of the human microbiome in womens health. The partnership between Ferring and MyBiotics has already successfully piloted technologies for stabilizing bacterial species critical to the female reproductive tract. The collaboration is expected to add several firsts to Ferrings microbiome product pipeline, including the companys first non-donor derived formulation and a live microbiota-based product specific to reproductive medicine.
Partners
growth-positive
https://www.jpost.com/Jpost-Tech/Biotechnology-General-opens-production-line-to-boost-manufacturing-capacity-603348
Biotechnology General (BTG), an Israeli-based company, has launched a production line that increases the capacity of mammalian drug production. The company invested $17 million in setting up the production line, which was established at its facilities in the Beer Tuvia Industrial Area in 2018. Ferring Pharmaceuticals, BTGs parent company, provided the investment. The inauguration of the production line was attended by Ferring President Per Falk, who highlighted the importance of BTG in Ferrings goal of becoming a world leader in reproductive medicine and maternal health. BTG is the oldest biological pharmaceutical company in Israel and has expanded over the years to become significant in the production of genetically engineered drugs.
InvestmentPartners
growth-positive
Ferring looks to Israel for innovative biotech
The article discusses the growth of Swiss company Ferring in the pharmaceutical sector. Ferring has achieved annual revenue of $2 billion by improving the user experience for older products, rather than relying on one bestselling drug. The companys focus on upgrading existing products and expanding into new markets has contributed to its success. Ferring also acquired Bio-Technology General (BTG), an Israeli biotechnology pioneer, which has further strengthened its position in the industry. Ferring is now investing in microbiome products and entering the urological-oncological field. The company aims to reinforce strengths in fertility, urology, and gastroenterology, while also improving access to treatment and the user experience for patients. The article suggests that Ferrings growth strategy could have an impact on the entire pharmaceutical industry.
InvestmentAcquisition
growth-positive
Ferring invests $15m in Israeli unit Bio-Technology General
Ferring Pharmaceuticals is investing $15 million to expand biotech production capabilities at its Israeli subsidiary Bio-Technology General (BTG). The investment will support the development of new treatments in reproductive medicine and womens health, as well as the manufacturing of the active pharmaceutical ingredient for Ferrings latest fertility treatment. The expansion will allow Ferring to maintain its scientific leadership in the fertility field and help more people around the world. BTG, founded in 1980, is the longest-standing bio-pharmaceutical company in Israel and has an R&D and manufacturing facility for female fertility, growth hormone, and osteoarthritis of the knees.
Investment
Ferring Pharmaceuticals Team
Employee Info
| Employees (range) | 51-200 |
| Exact count | 57 |
| Team members | 1 |
Similar Companies
Similar companies data is computed dynamically and not stored in the entity profile. This section requires implementing a similarity query (e.g. by classification overlap, sector, district).
Ferring Pharmaceuticals Internal
Recent Updates
Eran Levin
· eranl@sncentral.org · Automatic · 2024-12-05 15:10:05.000000
Maor Perlov
· maor.perlov@sncentral.org · Manual · 2022-11-04 14:17:55.000000
Maor Perlov
· maor.perlov@sncentral.org · Manual · 2022-11-04 14:27:14.000000
Eran Levin
· eranl@sncentral.org · Automatic · 2024-12-22 06:24:58.000000
Eran Levin
· eranl@sncentral.org · Automatic · 2024-08-07 05:07:36.000000
Eran Levin
· eranl@sncentral.org · Automatic · 2024-01-25 07:23:34.000000
Eran Levin
· eranl@sncentral.org · Automatic · 2024-01-25 16:24:24.000000
Eran Levin
· eranl@sncentral.org · Automatic · 2025-02-06 12:29:07.000000
Eran Levin
· eranl@sncentral.org · Automatic · 2024-01-25 07:23:34.000000
Maor Perlov
· maor.perlov@sncentral.org · Manual · 2022-11-04 14:27:02.000000
Maor Perlov
· maor.perlov@sncentral.org · Manual · 2022-11-04 13:15:17.000000
Maor Perlov
· maor.perlov@sncentral.org · Manual · 2022-11-04 14:20:18.000000
Eran Levin
· eranl@sncentral.org · Automatic · 2024-12-05 14:41:59.000000
Yamila Silbert
· yamila.urwicz@gmail.com · Manual · 2019-02-11 07:20:15.000000
Rom Lotan
· rom.lotan@gmail.com · Manual · 2018-12-30 21:59:21.000000
Yamila Silbert
· yamila.urwicz@gmail.com · Manual · 2019-02-11 07:21:44.000000
Yamila Silbert
· yamila.urwicz@gmail.com · Manual · 2019-02-11 07:20:33.000000
Yamila Silbert
· yamila.urwicz@gmail.com · Manual · 2018-05-24 11:36:21.000000
Yamila Silbert
· yamila.urwicz@gmail.com · Manual · 2018-01-18 14:58:43.000000
Yamila Silbert
· yamila.urwicz@gmail.com · Manual · 2018-01-18 14:58:43.000000
Yamila Silbert
· yamila.urwicz@gmail.com · Manual · 2018-01-18 14:58:43.000000
Yamila Silbert
· yamila.urwicz@gmail.com · Manual · 2018-01-18 14:58:43.000000
Yamila Silbert
· yamila.urwicz@gmail.com · Manual · 2018-01-18 14:58:43.000000
Yamila Silbert
· yamila.urwicz@gmail.com · Manual · 2018-01-18 14:58:43.000000
Yamila Silbert
· yamila.urwicz@gmail.com · Manual · 2018-01-18 14:58:43.000000
Yamila Silbert
· yamila.urwicz@gmail.com · Manual · 2018-01-18 14:58:43.000000
Yamila Silbert
· yamila.urwicz@gmail.com · Manual · 2018-01-18 14:58:43.000000
Yamila Silbert
· yamila.urwicz@gmail.com · Manual · 2018-01-18 14:59:55.000000
Katie McCandless
· katie.mccandless@gmail.com · Manual · 2017-01-20 13:13:13.000000
Katie McCandless
· katie.mccandless@gmail.com · Manual · 2017-01-20 13:13:13.000000
Note: Free-text notes visible in the original Finder "Internal" tab are not present in the imported profile data. Only the update audit log is available.
Admin Info
| Confidence | 62/100 |
| Missing | funding stage, product stage, sector, business model, video or image, funding rounds, markets, not claimed |
| BI Verification | Yanina Wainscheinker |
| Crunchbase | Ferring Pharmaceuticals |
| Phone | +97246309500 Ferring; +97288612009 BTG |
| Creator | Natalia Golczar |
| Creator email | ngolczar@gmail.com |
| Last updater | Maor Perlov |
| Updater email | maor.perlov@sncentral.org |
| Last update | 2022-11-04T00:00:00.000Z |
| Created | 2016-08-23T00:00:00.000Z |